INSM - インスメッド （Insmed Inc.） インスメッドINSMのチャート
INSMの企業情報
| symbol | INSM |
|---|---|
| 会社名 | Insmed Inc （インスメッド） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 インスメッド(Insmed Incorporated)は希少疾患セグメント患者の治療法の開発・商品化を通じて運営するバイオ医薬品会社である。リード製品候補は、マイコバクテリウム・アビウム複合体（MAC）によって引き起こされる治療不応性非結核性マイコバクテリア（NTM）肺疾患の成人患者のための後期段階にある吸入用LAI（ARIKAYCE）、または吸入用リポソームアミカシンである。その初期段階のパイプラインには、メチシリン耐性黄色ブドウ球菌およびNTMを含む、満たされていない医療ニーズの複数のまれな疾患で同社が評価している前臨床化合物が含まれる。初期の臨床段階のパイプラインにはINS1007とINS1009が含まれる。INS1007は、ジペプチジルペプチダーゼ1の経口可逆阻害剤である。INS1009は、肺動脈性高血圧症を含む稀な肺疾患のための差別化された製品プロファイルを提供し得るトレプロスチニルプロドラッグの吸入ナノ粒子製剤である。同社はINS1009の第I相試験を完了した。 インスメッドは、米国のバイオ医薬品メ―カ―。肺疾患の患者向けの吸入治療法を開発し、商品化する。主力製品候補は、肺感染症の吸入抗生物質治療薬「ARIKAYCE（吸入用のリポソ―ム性アミカシン）」である。非結核性抗酸菌症(NTM)による肺感染患者による第2相試験と、緑膿菌の肺感染を伴う嚢胞性線維症(CF)患者による第3相臨床試験を完了した。 Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United Statesand the European Union to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a growing footprint across Europeand in Japan. . |
| 本社所在地 | 10 Finderne Avenue Building 10 Bridgewater NJ 08807 USA |
| 代表者氏名 | William H. Lewis ウィリアムH.ルイス |
| 代表者役職名 | President Chief Executive Officer Director 社長兼最高経営責任者（CEO） |
| 電話番号 | +1 908-977-9900 |
| 設立年月日 | 36465 |
| 市場名 | NASDAQ National Market System |
| ipoyear | ―年 |
| 従業員数 | 214人 |
| url | www.insmed.com |
| nasdaq_url | https://www.nasdaq.com/symbol/insm |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -241.92400 |
| 終値（lastsale） | 16.93 |
| 時価総額（marketcap） | 1304301725.94 |
| 時価総額 | 時価総額（百万ドル） 1264.24 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 937.06700 |
| 当期純利益 | 当期純利益（百万ドル） -255.52400 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Insmed Incorporated revenues was not reported. Net loss increased 77% to $145M. Higher net loss reflects General and Administrative - other increase from $59K to $62.1M (expense) Research and development -other increase of 83% to $61.2M (expense) Interest expense increase from $3M to $12.1M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.32 to -$1.89. |
INSMのテクニカル分析
INSMのニュース
BofA Securities maintains Insmed at Buy with a price target of $35.00 2023/04/24 12:38:37 Investing.com
https://www.investing.com/news/pro/insmed-receives-investment-bank-analyst-rating-update-3062791
Insmed to Host First Quarter 2023 Financial Results Conference Call on Thursday, May 4, 2023 2023/04/20 12:00:00 PR Newswire
BRIDGEWATER, N.J., April 20, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its first quarter 2023 financial results on…
Insmed Completes Enrollment of Adult Patients in Phase 3 ASPEN Study of Brensocatib in Bronchiectasis 2023/03/31 12:00:00 PR Newswire
Topline Data Remains on Track to be Reported in Q2 of 2024 More than 1,700 Adult Patients Enrolled in Global, Registrational Study of First-in-Class Treatment Candidate BRIDGEWATER, N.J., March 31, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical…
Chronic Pulmonary Hypertension Treatment Market is Expected to Accumulate a Market Value of US$ 11.4 Billion by 2033, Growing at a CAGR of 5% | Future Market Insights, Inc. Report 2023/03/15 14:00:00 Accesswire
NEWARK, DE / ACCESSWIRE / March 15, 2023 / A report published by Future Market Insights predicts that the Chronic Pulmonary Hypertension Treatment Market will reach a valuation of US$ 7 billion in 2023 and is expected to accumulate a market value of US$ 11.4 billion by registering a CAGR of 5% in the forecast period 2023 to 2033. The market is expected to witness significant growth in the coming years, driven by the increasing prevalence of pulmonary hypertension and the growing availability of effective treatment options. Pulmonary hypertension is a condition in which the blood pressure in the pulmonary artery, which carries blood from the heart to the lungs, becomes abnormally high. This can cause the right side of the heart to work harder, leading to heart failure if left untreated. Pulmonary hypertension can be caused by a variety of factors, including genetics, heart and lung disease, and exposure to certain drugs or toxins. Request a Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16779 One of the key drivers of the chronic pulmonary hypertension treatment market is the increasing prevalence of the disease.
Can you now get a good deal on Insmed Incorporated’s shares? 2023/03/09 13:32:00 US Post News
The share price of Insmed Incorporated (NASDAQ:INSM) fell to $19.61 per share on Wednesday from $19.79. While Insmed Incorporated has underperformed by -0.91%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, INSM fell by -15.33%, with highs and lows ranging from $28.94 to $16.41, whereas the […]
How Is Insmed Incorporated (NASDAQ: INSM) Doing? 2022/05/25 15:30:00 Stocks Register
Insmed Incorporated (NASDAQ:INSM) price closed lower on Tuesday, May 24, dropping -4.15% below its previous close. >> 5 Best Growth Stocks for 2022 << >> 5 Best Growth Stocks for 2022 << A look at the daily price movement shows that the last close reads $20.01, with intraday deals fluctuated between $19.01 and $19.71. The … How Is Insmed Incorporated (NASDAQ: INSM) Doing? Read More »
Insmed stock rises 8% after director Melvin Sharoky buys shares worth $344,000 2022/05/16 19:22:58 Seeking Alpha
Insmed <> is trading higher after the company''s director Melvin Sharoky bought 20,000 shares of the stock for an average price of $17.2 per shareThe total value adds up…
Insmed Inc. (INSM) CEO Will Lewis on Q1 2022 Results - Earnings Call Transcript 2022/05/07 18:33:06 Seeking Alpha
Insmed Inc. (NASDAQ:NASDAQ:INSM) Q1 2022 Results Conference Call May 05, 2022 08:30 AM ET Company Participants Eleanor Barisser - IR Will Lewis - Chairman, CEO Sara Bonstein - CFO…
Insmed: Q1 Earnings Insights 2022/05/05 12:12:28 Benzinga
Insmed (NASDAQ: INSM ) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:30 AM. Here''s what investors need to know about the announcement. Earnings Insmed beat estimated earnings by 9.09%, reporting an EPS of $-0.8 versus an … Full story available on Benzinga.com
Insmed GAAP EPS of -$0.80 beats by $0.10, revenue of $53.1M misses by $0.26M 2022/05/05 11:39:37 Seeking Alpha
Insmed press release (INSM): Q1 GAAP EPS of -$0.80 beats by $0.10.Revenue of $53.1M (+32.1% Y/Y) misses by $0.26M.
Insmed Incorporated 2022 Q4 - Results - Earnings Call Presentation 2022/02/17 16:41:54 Seeking Alpha
Insmed GAAP EPS of -$0.95 misses by $0.05, revenue of $56.12M beats by $5.28M 2022/02/17 12:13:22 Seeking Alpha
Insmed press release (INSM): Q4 GAAP EPS of -$0.95 misses by $0.05.Revenue of $56.12M (+35.5% Y/Y) beats by $5.28M.The company expects full-year 2022 revenues for ARIKAYCE to…
Insmed Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business and Pipeline Update 2022/02/17 12:00:00 PR Newswire
BRIDGEWATER, N.J., Feb. 17, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the fourth quarter and full year ended December 31,…
Earnings Scheduled For February 17, 2022 2022/02/17 10:02:37 Benzinga
Companies Reporting Before The Bell • Palantir Technologies (NYSE: PLTR ) is estimated to report quarterly earnings at $0.04 per share on revenue of $417.69 million. • Organon (NYSE: OGN ) is expected to report quarterly earnings at $1.24 per share on revenue of $1.57 billion. • Perella Weinberg Partners (NASDAQ: PWP ) is likely to report quarterly earnings at $0.30 per share on revenue of $193.75 million. • Navios Maritime Partners (NYSE: NMM ) is estimated to report quarterly earnings at $4.35 per share on revenue of $272.59 million. • Portland General Electric (NYSE: POR ) is likely to report quarterly earnings at $0.76 per share on revenue of $533.13 million. • Frontline (NYSE: FRO ) is estimated to report quarterly earnings at $0.13 per share on revenue of $111.30 million. • R1 RCM (NASDAQ: RCM ) is estimated to report quarterly earnings at $0.11 per share on revenue of $399.26 million. • Fiverr International (NYSE: FVRR ) is likely to report quarterly earnings at $0.04 per share on revenue of $76.